ASTHHealthcare · Medical Care FacilitiesThe 11 Wall Street analysts covering Astrana Health, Inc. hold a median 12-month price target of $53 — +40.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 14 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Astrana Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (92): Sales and profits are climbing, and climbing faster than before.
Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ASTH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +40.5% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | Freedom Capital Markets | Maintains | Buy | $50 |
| 15 Sept 2026 | Oppenheimer | Initiates | Outperform | — |
| 15 Sept 2026 | Oppenheimer | Initiates | Outperform | $53 |
| 11 Aug 2026 | Truist Securities | Maintains | Buy | $47 → $55 |
| 11 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 7 Aug 2026 | Barclays | Maintains | Overweight | — |
| 7 Aug 2026 | Barclays | Maintains | Overweight | $50 → $53 |
| 14 July 2026 | BTIG | Maintains | Buy | $50 → $65 |
| 14 July 2026 | BTIG | Maintains | Buy | — |
| 14 July 2026 | TD Cowen | Maintains | Buy | — |
| 14 July 2026 | TD Cowen | Maintains | Buy | $45 → $50 |
| 2 June 2026 | BTIG | Reiterates | Buy | — |
| 26 May 2026 | Barclays | Upgrade | Overweight | — |
| 14 May 2026 | Truist Securities | Maintains | Buy | — |
| 12 May 2026 | TD Cowen | Maintains | Buy | — |
| 11 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 8 May 2026 | BTIG | Maintains | Buy | — |
| 8 May 2026 | Needham | Maintains | Buy | — |
| 15 Apr 2026 | Baird | Maintains | Outperform | — |
| 13 Mar 2026 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ASTH appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Astrana Health, Inc. returned +27.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 16% of US stocks
Cheaper than 82% of US stocks
Cheaper than 40% of US stocks
Cheaper than 27% of US stocks
Higher than 85% of US stocks
Higher than 85% of US stocks
Higher than 10% of US stocks
Higher than 52% of US stocks
Higher than 50% of US stocks
Higher than 57% of US stocks
Higher than 70% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Astrana Health, Inc. has a market value of $1.9B and an enterprise value of $2.3B.
Revenue in the twelve months to 30 June 2026: $3.8B. The latest quarter grew 48.5% year on year.
Net income over the same four quarters: $39.2M, a 1.0% net margin.
Diluted earnings per share, trailing twelve months: $0.82.
Free cash flow in the twelve months to 30 June 2026: $94.4M.
Astrana Health, Inc. spent $1.9M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 45.2×; forward P/E: 10.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Astrana Health, Inc. employs 3,000 people — $1.3M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Astrana Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Astrana Health said it will release financial results for the third quarter ended September 30, 2026, after market close on November 5, 2026.
Why it matters — ASTH watchers can note the scheduled date for the company's third-quarter results announcement.
Zacks Investment Research says Astrana Health has an impressive history of earnings surprises and currently has two key factors that could support a beat in its next quarterly report.
Why it matters — ASTH watchers may note the article’s favorable assessment of the company’s earnings-beat setup ahead of its next report.
SBS Law announced that investors in Astrana Health, Inc. have the opportunity to join a fraud investigation into the company. The announcement, released via Business Wire, invites ASTH investors to participate in the probe.
Why it matters — An active fraud investigation could signal potential legal or financial exposure for Astrana Health, a development that shareholders and market watchers would monitor closely.
AWKO Law LLP has announced it is investigating a data breach that resulted in unauthorized access to sensitive information of individuals affiliated with Astrana Health, Inc.'s subsidiary, Astrana Health Management, Inc. Astrana Health disclosed the unauthorized access to the SEC on September 23, 2026.
Why it matters — ASTH watchers would care because the data breach and resulting investigation raise potential legal, regulatory, and reputational concerns for the company.
Lowey Dannenberg, P.C. announced that it is investigating Astrana Health, Inc. (NASDAQ: ASTH) for potential violations of federal securities laws. The investigation was disclosed by the law firm on September 22, 2026.
Why it matters — A securities-law investigation into Astrana Health could signal potential legal exposure for the company and draw attention to undisclosed issues for investors.
The 11 Wall Street analysts covering Astrana Health, Inc. have a median 12-month price target of $53, with estimates ranging from $41 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Astrana Health, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Astrana Health, Inc. 69 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Astrana Health, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +40.5% from the last close, and Ticker Nerd's factor model ranks Astrana Health, Inc. 69 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Astrana Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $41 to $65 over the next 12 months.
Astrana Health, Inc. returned +27.2% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Astrana Health Inc. is a physician-centric healthcare management company that provides integrated medical care services in the United States.
The most recent item we track (PRNewsWire, 9 Oct 2026): "Astrana Health, Inc. Schedules 2026 Third Quarter Financial Results Release and Conference Call". Astrana Health said it will release financial results for the third quarter ended September 30, 2026, after market close on November 5, 2026.
Astrana Health Inc. is a physician-centric healthcare management company that provides integrated medical care services in the United States. Its platform combines care coordination, population health management, and technology-enabled support to help physicians, specialists, hospitals, and health plans deliver coordinated, value-based care. The company operates through three main segments: Care Partners, Care Delivery, and Care Enablement. These businesses work together to support primary care, multi-specialty care, immediate care, radiology, laboratory services, and other clinical and administrative functions across its network. Astrana Health serves patients covered by public and private insurance, as well as uninsured patients, with a focus on improving care delivery across complex healthcare settings. Headquartered in Alhambra, California, Astrana Health plays a role in the healthcare services market by linking clinical operations with technology and risk-bearing care models.
CEO Mr. Brandon K. Sim M.S. · 3,000 employees · United States · https://www.astranahealth.com
